Results 51 to 60 of about 53,092 (237)

LC3B Mediated SETDB1‐Accounted Alcoholic Steatohepatitis via Lipidation‐Dependent LAP and Lipidation‐Independent Nuclear Stabilization

Advanced Science, EarlyView.
SETDB1 is progressively downregulated in ALD, correlating with disease severity. SETDB1 deficiency impairs LAP by disrupting Rubicon membrane localization, leading to defective lipid droplet clearance. Concurrently, loss of SETDB1 reduces nuclear LC3B, causing R‐loop accumulation and cGAS‐STING‐driven inflammation. Lipidated LC3B mediates LAP‐dependent
Yi Zhang, Tan Wei, Jiahang Wu, Chuixu Lin, Dongbo Zhu, Yanhui Li, Shuting Shi, Shishun Huang, Leiming Jiang, Hongzhi Wang, Meiqi Song, Pengfei Gao, Xu Wu, Mingjian Fan, Chaofeng Wei, Qian Wang, Lihui Qu, Zhigang Wang   +17 more
wiley   +1 more source

Rapid development of non-alcoholic steatohepatitis in Psammomys obesus (Israeli sand rat). [PDF]

PLoS ONE, 2014
BACKGROUND AND AIMS: A major impediment to establishing new treatments for non-alcoholic steatohepatitis is the lack of suitable animal models that accurately mimic the biochemical and metabolic characteristics of the disease.
Briana Spolding, Timothy Connor, Carrie Wittmer, Lelia L F Abreu, Antony Kaspi, Mark Ziemann, Gunveen Kaur, Adrian Cooper, Shona Morrison, Scott Lee, Andrew Sinclair, Yann Gibert, James L Trevaskis, Jonathon D Roth, Assam El-Osta, Richard Standish, Ken Walder   +16 more
doaj   +1 more source

Two-dimensional shear wave elastography and ultrasound-guided attenuation parameter for progressive non-alcoholic steatohepatitis.

PLoS ONE, 2021
Background and aimsWe investigated the usefulness of combining two-dimensional shear wave elastography and the ultrasound-guided attenuation parameter for assessing the risk of progressive non-alcoholic steatohepatitis, defined as non-alcoholic ...
Hidekatsu Kuroda, Yudai Fujiwara, Tamami Abe, Tomoaki Nagasawa, Takuma Oguri, Sachiyo Noguchi, Naohisa Kamiyama, Yasuhiro Takikawa   +7 more
doaj   +1 more source

Gut Mycobiota‐Associated Tryptophan Catabolites Protect Against Metabolic Dysfunction‐Associated Steatotic Liver Disease

Advanced Science, EarlyView.
ABSTRACT Accumulating evidence suggests that the intestinal microbiota participates in the progression of metabolic dysfunction‐associated steatotic liver disease (MASLD) through microbiota‐host interaction. However, the beneficial role of commensal mycobiota in MASLD progression remains poorly understood.
Shuping Qiao, Shuangya Fan, Juan Xu, Zhen Xu, Chen Peng, Junxing Qu, Ziqian Bing, Shizhen Zhou, Sunan Shen, Guifang Xu, Yue Zhao, Tingting Wang   +11 more
wiley   +1 more source

Viability assessment and transplantation of fatty liver grafts using end‐ischemic normothermic machine perfusion

Liver Transplantation, EarlyView., 2022
Abstract End‐ischemic viability testing by normothermic machine perfusion (NMP) represents an effective strategy to recover liver grafts having initially been discarded for liver transplantation (LT). However, its results in the setting of significant (≥30%) macrovesicular steatosis (MaS) have not been specifically assessed.
Damiano Patrono, Riccardo De Carlis, Alessandro Gambella, Francesca Farnesi, Alice Podestà, Andrea Lauterio, Francesco Tandoi, Luciano De Carlis, Renato Romagnoli   +8 more
wiley   +1 more source

Therapies for non-alcoholic steatohepatitis

Liver Research, 2017
Current phase 3 trials for the treatment of non-alcoholic steatohepatitis (NASH) are discussed in this review. Modalities that are based on weight loss include therapeutic lifestyle changes, pharmacological weight loss drugs (e.g., orlistat), and ...
Winston Dunn
doaj   +1 more source

BIN1 and ALDH1B1 Deficiency in Colonic Smooth Muscle Drives Mitochondrial Dysfunction and Fibrosis in Slow‐Transit Constipation

Advanced Science, EarlyView.
Slow‐transit constipation (STC) is a disabling motility disorder with unclear smooth‐muscle mechanisms. Spatial proteomic analysis of STC patient colon reveals both the central pathogenic role of smooth muscle cells (SMCs) in STC and novel regulators of intestinal motility, BIN1 and ALDH1B1.
Jianbo Liu, Hao Zhang, Wenhao Qiao, Ran Liu, Jie Sun, Xiaopei Li, Qin Li, Dongbo Zhao, Dawei Chen, Jingxin Li, Shuxiao Dong   +10 more
wiley   +1 more source

The Neutrophil-to-Lymphocyte Ratio as A Noninvasive Marker in Patients with Biopsy-Proven Non-Alcoholic Steatohepatitis

İstanbul Medical Journal, 2016
Objective: Non-alcoholic fatty liver disease is a global health problem with an increasing prevalence. The neutrophil-to-lymphocyte ratio is a cheap inflammatory parameter that can be easily calculated from routine complete blood count tests.
Mehmet Asıl, Ramazan Dertli
doaj   +1 more source

Master Regulator SMC1A, Stabilized by N6‐Methyladenosine Reader IGF2BP1, Promotes HCC Progression Through Facilitating Enhancer–Promoter Interaction of Nestin

Advanced Science, EarlyView.
IGF2BP1‐mediated m6A stabilization sustains SMC1A expression, enabling cohesin‐associated chromatin regulation of Nestin in hepatocellular carcinoma. This work reveals an epitranscriptomic‐chromatin‐cytoskeletal regulatory axis linked to malignant phenotypes and identifies SMC1A as a biologically relevant vulnerability in HCC.
Zhenxiang Peng, Diguang Wen, Lu Zeng, Lin Lv, Shengtao Liao, Wenguang Zhang, Zhechuan Mei, Chuanfei Li   +7 more
wiley   +1 more source

Therapeutic approaches for non-alcoholic steatohepatitis

Therapeutic Advances in Endocrinology and Metabolism, 2021
Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) have been reported as a novel worldwide epidemic, very often associated with obesity, metabolic syndrome, and type 2 diabetes.
Luc F. Van Gaal, Jonathan Mertens, Sven Francque, Christophe De Block   +3 more
doaj   +1 more source